Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2362-2379
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2362
Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer
Yi Zhou, Shuang Wu, Fan-Jie Qu
Yi Zhou, Shuang Wu, Fan-Jie Qu, Department of Oncology, Affiliated Dalian Third People’s Hospital of Dalian Medical University, Dalian 116033, Liaoning Province, China
Author contributions: Zhou Y initiated the work and designed the idea; Qu FJ, Wu S, and Zhou Y prepared and collected the material and data; Zhou Y and Qu FJ wrote the paper. All authors have read and approved the final manuscript.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior authors or other coauthors who contributed their efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fan-Jie Qu, Doctor, MD, Chief Physician, Professor, Department of Oncology, Affiliated Dalian Third People’s Hospital of Dalian Medical University, No. 40 Qianshan Road, Dalian 116033, Liaoning Province, China. wyb960419@163.com
Received: December 7, 2023
Peer-review started: December 7, 2023
First decision: February 6, 2024
Revised: February 13, 2024
Accepted: April 1, 2024
Article in press: April 1, 2024
Published online: June 15, 2024
Processing time: 190 Days and 20.8 Hours
Core Tip

Core Tip: This review focuses on therapies targeting the epidermal growth factor receptor (EGFR) signaling pathway in metastatic colorectal cancer, mainly including: (1) Treatment targeting rat sarcoma (RAS) status, including RAS wild type, maintenance therapy with anti-EGFR monoclonal antibody, anti-EGFR re-challenge therapy, treatment targeting NoeRAS and Kirsten RAS viral oncogene G12C mutations; (2) treatment for patients with B-type RAF mutations; and (3) treatment targeting human EGFR2 amplification or overexpression.